<DOC>
	<DOC>NCT02848521</DOC>
	<brief_summary>This is a prospective, non-interventional study (NIS) measuring health-related quality of life (HRQoL), treatment satisfaction, and other patient-reported outcomes (PROs) of ADPKD patients in Europe.</brief_summary>
	<brief_title>A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<criteria>Male and female aged â‰¥ 18 years. Patient has a diagnosis of ADPKD between CKD Stages 13, and is deemed by their treating physician to likely have rapidly progressing disease. Patient has a life expectancy greater than 18 months at time of enrolment. Patient is able and willing to give informed consent, if required according to local regulations. Patient is fluent in local language. Patient is currently participating in, or has in the last 12 months participated in an interventional clinical trial. Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient. Inability of the patient to complete PROs remotely.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>CKD</keyword>
	<keyword>Rapid progressor</keyword>
	<keyword>quality of life</keyword>
	<keyword>DCE</keyword>
</DOC>